Pelvic relapses in ovarian cancer. Role of CA-125, transvaginal ultrasound and color Doppler.
From January 1995 to January 2001, 40 patients with epithelial ovarian cancer were treated at our Institution. Fourteen of these, with a clinical CR after surgery and platinum-based chemotherapy, were evaluated monthly by gynecological examination, Ca-125 RIA assay, pelvic ultrasound with transabdominal and transvaginal probe and color Doppler. Six pelvic relapses, from 1.5 to 3.0 cm, were detected by transvaginal ultrasound (US). They showed a rich neovascularization with low resistance, high flow, PI from 0.3 to 1.0 and RI < 0.5 in all cases. US did not reveal any sign of relapse in the remaining eight patients. In all cases of pelvic relapses ultrasonic signs of recurrence preceded the increase of Ca-125 by one to six months (average 3.8).
Caserta
D
D
Department of Experimental Medicine, University of L'Aquila, Italy.
Marci
R
R
Porzio
G
G
Di Roma
E
E
Moscarini
M
M
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D018394:CA-125 Antigen / Q000032:analysis*; D002277:Carcinoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D019160:Endosonography / Q000379:methods*; D005260:Female; D006801:Humans; D007558:Italy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D010386:Pelvic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D011863:Radioimmunoassay; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D015996:Survival Rate; D018615:Ultrasonography, Doppler, Color / Q000379:methods*
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen